The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia

American Journal of Hematology

Volumn 86, Issue 7, 2011, Pages 567-572

  Banwait, Ranjit ^a   O'Regan, Kevin ^a   Campigotto, Federico ^a   Harris, Brianna ^a   Yarar, Dilek ^a   Bagshaw, Meghan ^a   Leleu, Xavier ^a,b   Leduc, Renee ^a   Ramaiya, Nikhil ^a   Weller, Edie ^a   Ghobrial, Irene M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN M; RITUXIMAB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; PYRAZINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE MARROW EXAMINATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION COEFFICIENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATOSPLENOMEGALY; HUMAN; LYMPHADENOPATHY; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PYRAZINES; RADIOPHARMACEUTICALS; WALDENSTROM MACROGLOBULINEMIA;

EID: 79959361406     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22044     Document Type: Article

References (23)

1. Treon SP. How I treat Waldenstrom's macroglobulinemia. Blood 2009; 114: 2375-2385.
2. Vijay A, Gertz MA. Current treatment options for Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma 2008; 8: 219-229.
3. Ghobrial IM, Witzig TE. Waldenstrom macroglobulinemia. Curr Treat Options Oncol 2004; 5: 239-247.
4. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol 2003; 4: 679-685.
5. Weber D, Treon SP, Emmanouilides C, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 127-131.
6. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006; 6: 380-383.
7. Moulopoulos LA, Dimopoulos MA, Varma DGK, et al. Waldenstrom Macroglobulinemia: MR imaging of the spine and CT of the abdomen and pelvis. Radiology 1993; 188: 669-673.
8. Elmonayeri MS, Elgazzar AH. Scintigraphic pattern of skeletal involvement of Waldenstrom macroblobulinemia. Clin Nucl Med 2008; 33: 585-586.
9. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133: 158-164.
10. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-4471.
11. Ng AP, Wirth A, Seymour JF, et al. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma 2007; 48: 596-600.
12. Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004; 91: 850-854.
13. Najjar F, Hustinx R, Jerusalem G, et al. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm 2001; 16: 297-304.
14. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma 2000; 39: 543-553.
15. Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12: 825-830.
16. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.
17. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 110-115.
18. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47: 1059-1066.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors. Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
20. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
21. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005; 46: 958-963.
22. Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 22-28.
23. Shah N, Hoskin P, McMillan A, et al. The impact of FDG positron emission tomography imaging on the management of lymphomas. Br J Radiol 2000; 73: 482-487.